https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16776 Wed 11 Apr 2018 17:08:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23244 Thu 04 Nov 2021 10:39:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20551 Sat 24 Mar 2018 08:02:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41881 Mon 15 Aug 2022 14:09:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44148 Mon 10 Oct 2022 09:17:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19927 Mon 06 Aug 2018 11:18:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32801 Fri 03 Dec 2021 10:34:55 AEDT ]]>